Comparison of the effects of etomidate, propofol, and their combination on heart rate and blood pressure during anesthesia induction and intubation.

Haemodynamic Effects of Etomidate, Propofol and Their Combination on Induction and Intubation: A Prospective Randomized Clinical Trial - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/0103301

Enrollment

Registered

2026-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: combination of etomidate and propofol: Participants will be randomly allocated into three groups. Group E will receive intravenous etomidate 0.3 mg/kg, Group P will receive intravenous

Eligibility

Inclusion criteria

Inclusion criteria: ASA1 ASA2

Exclusion criteria

Exclusion criteria: ASA 3 ASA 4 PREGNANT PATIENT PATIENTS WITH CARDIAC PROBLEMS

Design outcomes

Primary

Measure	Time frame
To compare the hemodynamic responses specifically changes in heart rate and mean arterial pressure during induction and immediately after laryngoscopy and endotracheal intubation among patients receiving etomidate, propofol, and their combinationTimepoint: Hemodynamic variables will be recorded at baseline, post-induction, pre-intubation, at intubation, and at 1, 3, and 5 minutes following endotracheal intubation.	—

Measure

Time frame

To compare the hemodynamic responses specifically changes in heart rate and mean arterial pressure during induction and immediately after laryngoscopy and endotracheal intubation among patients receiving etomidate, propofol, and their combinationTimepoint: Hemodynamic variables will be recorded at baseline, post-induction, pre-intubation, at intubation, and at 1, 3, and 5 minutes following endotracheal intubation.

—

Secondary

Measure	Time frame
Secondary outcomes include incidence of hypotension, hypertension, tachycardia and bradycardia; requirement of rescue medications; quality of intubating conditions; incidence of myoclonus, pain on injection, oxygen desaturation, and need for additional induction agents.Timepoint: Secondary outcomes were assessed from induction until 5 minutes after endotracheal intubation. Hemodynamic adverse events and rescue drug requirements were recorded at baseline, post-induction, pre-intubation, at intubation, and at 1, 3, and 5 minutes post-intubation. Drug-related adverse effects and intubating conditions were assessed during induction and intubation.	—

Measure

Time frame

Secondary outcomes include incidence of hypotension, hypertension, tachycardia and bradycardia; requirement of rescue medications; quality of intubating conditions; incidence of myoclonus, pain on injection, oxygen desaturation, and need for additional induction agents.Timepoint: Secondary outcomes were assessed from induction until 5 minutes after endotracheal intubation. Hemodynamic adverse events and rescue drug requirements were recorded at baseline, post-induction, pre-intubation, at intubation, and at 1, 3, and 5 minutes post-intubation. Drug-related adverse effects and intubating conditions were assessed during induction and intubation.

—

Countries

India

Contacts

Public ContactDr Rajalakshmi R

Vinayaka Missions Kirupananda Variyar Medical college and Hospitals

cruise2010.mmc@gmail.com9840623673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026